San Diego-based Viking Therapeutics marked itself as a serious competitor during the weight loss drug current market in February right after revealing promising data from the mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection As well as in March the c